Dear Dr. Gott: I have been plagued for years by an incurable skin condition I am told is called prurigo nodularis. I have tried a sunlight box and a tanning bed, as well as cortisone injections ...

Opens in a new tab or window The FDA has approved dupilumab (Dupixent) as the first treatment with an indication for prurigo nodularis, Sanofi and Regeneron announced. A chronic inflammatory skin ...

Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the ...

The debilitating signs and symptoms of prurigo nodularis can negatively impact health-related quality of life, including mental health, activities of daily living and social interactions.

Kiniksa’s Breakthrough Therapy application was based on data from the Phase 2a clinical trial of vixarelimab in prurigo nodularis. The Phase 2a trial met its primary efficacy endpoint ...

Currently, there are no approved topicals for the treatment of prurigo nodularis. According to the presenter, ruxolitinib cream 1.5% could become the first. ORLANDO — Ruxolitinib cream 1.5% ...

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...

A week after scoring the first FDA approval for eosinophilic esophagitis, the drug scored priority review for prurigo nodularis. If it wins the agency's blessing, Dupixent would be the first FDA ...

ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within ...

regulatory filings for prurigo nodularis planned in the first half of 2022 The randomized, placebo-controlled PRIME2 trial met primary and all key secondary endpoints with data presented at AAD ...